Deutsche Bank assumed coverage on shares of Diplomat Pharmacy (NYSE:DPLO) in a report issued on Thursday, BenzingaRatingsTable reports. The brokerage issued a sell rating and a $4.00 target price on the stock.
Several other equities analysts have also commented on DPLO. ValuEngine raised Diplomat Pharmacy from a buy rating to a strong-buy rating in a research report on Thursday, August 1st. Zacks Investment Research downgraded Diplomat Pharmacy from a hold rating to a sell rating in a report on Wednesday, August 14th. Wells Fargo & Co lifted their price objective on Diplomat Pharmacy from $5.00 to $5.50 and gave the stock a market perform rating in a report on Tuesday, August 13th. Finally, Barclays set a $7.00 price objective on Diplomat Pharmacy and gave the stock a buy rating in a report on Friday, August 9th. Four analysts have rated the stock with a sell rating, nine have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. Diplomat Pharmacy presently has a consensus rating of Hold and a consensus price target of $9.43.
Diplomat Pharmacy stock traded down $0.35 during midday trading on Thursday, hitting $5.64. 86,116 shares of the company were exchanged, compared to its average volume of 740,879. The company’s fifty day moving average price is $5.60 and its 200-day moving average price is $5.55. The company has a market cap of $502.00 million, a PE ratio of 28.35 and a beta of 1.01. The company has a debt-to-equity ratio of 1.53, a current ratio of 0.99 and a quick ratio of 0.66. Diplomat Pharmacy has a fifty-two week low of $4.17 and a fifty-two week high of $21.48.
Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings results on Friday, August 9th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The company had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.23 billion. Diplomat Pharmacy had a negative return on equity of 4.01% and a negative net margin of 8.93%. The business’s revenue was down 9.1% on a year-over-year basis. During the same period last year, the firm posted ($0.05) earnings per share. On average, analysts expect that Diplomat Pharmacy will post -0.78 EPS for the current fiscal year.
A number of hedge funds have recently bought and sold shares of the business. Royal Bank of Canada increased its holdings in shares of Diplomat Pharmacy by 184.8% in the 2nd quarter. Royal Bank of Canada now owns 4,782 shares of the company’s stock valued at $29,000 after acquiring an additional 3,103 shares during the last quarter. KBC Group NV bought a new stake in shares of Diplomat Pharmacy in the 2nd quarter valued at approximately $46,000. Bank of Montreal Can increased its holdings in shares of Diplomat Pharmacy by 138.4% in the 2nd quarter. Bank of Montreal Can now owns 11,444 shares of the company’s stock valued at $70,000 after acquiring an additional 6,644 shares during the last quarter. BNP Paribas Arbitrage SA increased its holdings in shares of Diplomat Pharmacy by 446.9% in the 1st quarter. BNP Paribas Arbitrage SA now owns 13,104 shares of the company’s stock valued at $76,000 after acquiring an additional 10,708 shares during the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. bought a new stake in shares of Diplomat Pharmacy in the 2nd quarter valued at approximately $77,000. Institutional investors own 85.96% of the company’s stock.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Featured Story: Using other technical indicators with support levels
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.